Abstract #0918

Biodistribution of ferumoxytol: a longitudinal MRI study

Tilman Schubert^1,2, Utaroh Motosugi³, Diego Hernando¹, Camilo A Campo¹, Samir Sharma⁴, Scott Reeder^1,4,5,6,7, and Shane Wells¹

¹Radiology, University of Wisconsin Madison, Madison, WI, United States, ²Clinic for Radiology and Nuclear Medicine, Basel University Hospital, Basel, Switzerland, ³Department of Radiology, University of Yamanashi, Yamanashi, Japan, ⁴Medical Physics, University of Wisconsin Madison, Madison, WI, United States, ⁵Biomedical Engineering, University of Wisconsin Madison, Madison, WI, United States, ⁶Medicine, University of Wisconsin Madison, Madison, WI, United States, ⁷Emergency Medicine, University of Wisconsin Madison, Madison, WI, United States

Ferumoxytol has gained increasing interest as a negative MR-contrast agent due to its high r2* relaxivity. However, limited data is available about the temporal course of the biodistribution of ferumoxytol. This study evaluated the biodistribution of ferumoxytol in different tissue types using repeated MR-measurements until the 30th day after administration. Our longitudinal MRI-study demonstrated that tissues of the monocyte−macrophage system show different, dose dependent R2* peaks after ferumoxytol injection. These results could help to determine the optimal, tissue specific imaging delay after ferumoxytol administration. Tissues not containing monocytes/macrophages parallel the time course of ferumoxytol in the blood pool.

This abstract and the presentation materials are available to members only; a login is required.

Join Here